Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
AGLE Aeglea BioTherapeutics, Inc. daily Stock Chart
AGLE [NASD]
Aeglea BioTherapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.82 Insider Own1.20% Shs Outstand23.10M Perf Week-8.68%
Market Cap191.96M Forward P/E- EPS next Y-2.17 Insider Trans-2.12% Shs Float19.04M Perf Month-16.06%
Income-31.90M PEG- EPS next Q-0.39 Inst Own78.20% Short Float4.03% Perf Quarter-9.28%
Sales6.60M P/S29.09 EPS this Y18.80% Inst Trans-1.21% Short Ratio3.47 Perf Half Y-19.08%
Book/sh3.57 P/B2.33 EPS next Y-18.20% ROA-47.30% Target Price19.33 Perf Year75.32%
Cash/sh3.13 P/C2.66 EPS next 5Y- ROE-52.20% 52W Range3.75 - 12.00 Perf YTD53.60%
Dividend- P/FCF- EPS past 5Y- ROI-55.00% 52W High-30.75% Beta-
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin- 52W Low121.60% ATR0.63
Employees50 Current Ratio12.80 Sales Q/Q60.00% Oper. Margin- RSI (14)44.19 Volatility8.20% 6.83%
OptionableYes Debt/Eq0.00 EPS Q/Q2.70% Profit Margin- Rel Volume0.54 Prev Close8.07
ShortableYes LT Debt/Eq0.00 EarningsNov 06 Payout- Avg Volume221.12K Price8.31
Recom2.20 SMA20-5.25% SMA50-7.70% SMA200-9.22% Volume120,404 Change2.97%
Sep-04-18Downgrade Wells Fargo Outperform → Market Perform
Apr-24-18Initiated Evercore ISI Outperform $37
Mar-14-18Reiterated Needham Buy $8 → $12
Nov-14-18 07:45AM  Report: Exploring Fundamental Drivers Behind Aeglea BioTherapeutics, Barnes & Noble Education, GSI Technology, Morgan Stanley, FTS International, and Crown Crafts New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-08-18 09:12AM  Aeglea: 3Q Earnings Snapshot Associated Press
08:00AM  Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights GlobeNewswire
Oct-26-18 08:00AM  Aeglea BioTherapeutics to Present Preclinical Data on a New Pipeline Therapeutic for Cystinuria in an Oral Presentation at the 2018 American Society of Nephrology (ASN) Annual Meeting GlobeNewswire
Oct-22-18 08:00AM  Aeglea BioTherapeutics Announces Positive Interim Clinical Data for Pegzilarginase in Advanced Melanoma Patients at the European Society for Medical Oncology 2018 Congress GlobeNewswire
Oct-19-18 08:00AM  Aeglea BioTherapeutics to Present Preclinical Data on New Pipeline Therapeutic for Homocystinuria at 2018 American Society of Human Genetics (ASHG) Conference GlobeNewswire -6.06%
Oct-17-18 07:00AM  Aeglea BioTherapeutics Announces New Positive Interim Clinical Data and Improvements in Disease Manifestations for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency GlobeNewswire
Oct-10-18 08:00AM  Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 ASHG Annual Meeting GlobeNewswire -7.05%
Oct-01-18 08:00AM  FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency GlobeNewswire
Sep-28-18 02:14PM  Is Now The Right Time To Invest In Healthcare And Aeglea BioTherapeutics Inc (NASDAQ:AGLE)? Simply Wall St.
Sep-17-18 08:00AM  Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology GlobeNewswire
Sep-04-18 03:03PM  Aeglea Plunges On Updated Data For Arginase 1 Deficiency Candidate, Wells Fargo Downgrade Benzinga -15.46%
Aug-28-18 08:00AM  Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference GlobeNewswire
Aug-27-18 08:00AM  Aeglea BioTherapeutics to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018 SSIEM Annual Symposium GlobeNewswire
Aug-20-18 09:00AM  George Soros Bought This Under-the-Radar Biotech Stock: Should You? Motley Fool
Aug-09-18 08:38AM  Aeglea: 2Q Earnings Snapshot Associated Press +5.86%
08:00AM  Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 04:00PM  Aeglea BioTherapeutics Announces Fall 2018 Medical Conference Schedule GlobeNewswire
Jul-19-18 04:00PM  Aeglea BioTherapeutics Appoints Dr. Anthony G. Quinn as President and Chief Executive Officer GlobeNewswire
Jul-16-18 08:00AM  Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors GlobeNewswire
Jul-03-18 03:27PM  Alkermes' Aristada Initio Approved by FDA for Schizophrenia Zacks -5.55%
Jun-29-18 04:00PM  Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-25-18 09:12AM  Novo Nordisk (NVO) Announces Results in Diabetes Studies Zacks
Jun-21-18 04:14PM  Anika Reports Top Line Data from CINGAL Study, Shares Slump Zacks
Jun-20-18 05:51PM  Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs Zacks
05:03PM  Alexion (ALXN) Submits Application for ALXN1210 with FDA Zacks
03:54AM  Agios (AGIO) Initiates Phase III Study on PK Deficiency Drug Zacks
Jun-15-18 02:00PM  Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone Zacks
Jun-14-18 05:55PM  Flex Pharma Down on Workforce Reduction, Ends Phase II Study Zacks
04:44PM  Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA Zacks
10:50AM  BMO: Aeglea Has A Potentially Market-Conquering Arginase Deficiency Candidate, Oncology Opportunity Benzinga
May-31-18 11:23AM  5 Biotech Stocks to Boost Your Portfolios Health This Year InvestorPlace
May-15-18 08:00AM  Aeglea BioTherapeutics to Present at UBS Global Healthcare Conference GlobeNewswire
May-08-18 08:13AM  Aeglea: 1Q Earnings Snapshot Associated Press
08:00AM  Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-18-18 10:50PM  Aeglea BioTherapeutics Prices Public Offering of Common Stock GlobeNewswire -9.87%
Apr-17-18 04:01PM  Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Apr-12-18 07:00AM  Aeglea BioTherapeutics Presents New Phase 1/2 Trial Data Demonstrating Clinically Relevant Treatment Effects in Arginase 1 Deficiency Patients at the 2018 ACMG Annual Clinical Genetics Meeting GlobeNewswire +7.02%
Apr-05-18 08:00AM  Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting GlobeNewswire
Apr-03-18 08:53AM  Aeglea Initiates Lung Cancer Combination Study With Keytruda Zacks
08:00AM  Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting GlobeNewswire
Apr-02-18 08:00AM  Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials GlobeNewswire
Apr-01-18 11:21PM  Edited Transcript of AGLE earnings conference call or presentation 13-Mar-18 12:00pm GMT Thomson Reuters StreetEvents
Mar-26-18 08:00AM  Aeglea BioTherapeutics Appoints Dr. Ivana Magovevi-Liebisch to Board of Directors GlobeNewswire
Mar-20-18 08:00AM  Aeglea BioTherapeutics to Present at 17th Annual Needham Healthcare Conference GlobeNewswire
Mar-15-18 09:26PM  Want To Invest In Aeglea Biotherapeutics Inc (NASDAQ:AGLE)? Heres How It Performed Lately Simply Wall St. +6.72%
Mar-13-18 07:00AM  Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency and Reports Q4 and Full Year 2017 Financial Results GlobeNewswire
Mar-08-18 08:00AM  Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase GlobeNewswire +16.45%
Mar-06-18 04:21PM  Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders GlobeNewswire
Jan-18-18 04:05PM  Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference GlobeNewswire
Dec-28-17 11:46AM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:52AM  Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-17-17 03:24PM  Weekly CFO Buys Highlight GuruFocus.com
Dec-13-17 06:04PM  Has Aeglea Biotherapeutics Inc (NASDAQ:AGLE) Got Enough Cash To Cover Its Short-Term Obligations? Simply Wall St.
Dec-07-17 04:05PM  Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-29-17 10:49AM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 29, 2017 Capital Cube
08:00AM  Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102) GlobeNewswire
Nov-07-17 05:19PM  Aeglea reports 3Q loss Associated Press
04:05PM  Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-02-17 04:07PM  Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
11:40AM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : November 2, 2017 Capital Cube
Oct-17-17 09:33AM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : October 17, 2017 Capital Cube
Oct-16-17 08:00AM  Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aegleas AEB1102 (pegzilarginase) with Mercks KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer GlobeNewswire
Sep-06-17 07:00AM  Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency GlobeNewswire +5.21%
Aug-31-17 05:07PM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : August 31, 2017 Capital Cube +5.66%
04:05PM  Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference GlobeNewswire
Aug-25-17 11:46AM  Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube +5.47%
Aug-09-17 09:20PM  Aeglea reports 2Q loss Associated Press -6.58%
04:01PM  Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-20-17 04:17PM  Aeglea Bio shares down 2% after CEO resigns MarketWatch
04:01PM  Aeglea BioTherapeutics Announces Leadership Change GlobeNewswire
Jul-10-17 04:01PM  Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer GlobeNewswire +7.96%
Jun-06-17 09:20AM  Aeglea BioTherapeutics Prices Public Offering of Common Stock GlobeNewswire -15.73%
Jun-05-17 04:01PM  Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
May-25-17 10:42AM  Bristol-Myers' Opdivo Gets Priority Review for Liver Cancer Zacks -6.74%
May-24-17 11:08AM  Achaogen's Plazomicin Gets Breakthrough Therapy Designation Zacks -14.72%
May-23-17 08:00AM  Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update GlobeNewswire -10.16%
May-17-17 09:59AM  Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss Zacks
May-16-17 04:01PM  Aeglea BioTherapeutics to Present at the UBS 2017 Global Healthcare Conference GlobeNewswire
May-11-17 04:02PM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : May 11, 2017 Capital Cube
May-10-17 10:54AM  Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 Capital Cube
May-09-17 09:33AM  Aeglea reports 1Q loss Associated Press
08:00AM  Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-28-17 03:39PM  ETFs with exposure to Aeglea Biotherapeutics, Inc. : April 28, 2017 Capital Cube
Apr-13-17 10:52AM  New Strong Buy Stocks for April 13th Zacks
Mar-30-17 02:24PM  Edited Transcript of AGLE earnings conference call or presentation 23-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
Mar-29-17 04:05PM  Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting GlobeNewswire
01:04PM  AEGLEA BIOTHERAPEUTICS, INC. Financials
Mar-28-17 04:05PM  Aeglea BioTherapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-27-17 08:39AM  Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 27, 2017 Capital Cube
08:39AM  Aeglea Biotherapeutics, Inc. :AGLE-US: Earnings Analysis: Q4, 2016 By the Numbers : March 27, 2017
Mar-24-17 08:02AM  AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-23-17 04:39PM  Aeglea reports 4Q loss Associated Press -5.06%
04:30PM  Aeglea Bio Therapeutics Inc Earnings Call scheduled for 4:30 pm ET today
04:07PM  AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:05PM  Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
08:00AM  Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting GlobeNewswire
07:07AM  Q4 2016 Aeglea Bio Therapeutics Inc Earnings Release - After Market Close
Mar-17-17 08:00AM  Aeglea BioTherapeutics to Announce Fourth Quarter and Full-Year 2016 Financial Results on Thursday, March 23 GlobeNewswire +7.65%
Mar-06-17 04:01PM  AEGLEA BIOTHERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuchart AaronChief Business OfficerSep 27Sale9.506,00057,0052,500Sep 28 05:11 PM
Schuchart AaronChief Business OfficerAug 17Option Exercise3.508,50029,7508,500Aug 21 04:24 PM
GEORGIOU GEORGEDirectorAug 13Option Exercise5.9137,333220,784175,861Aug 15 04:40 PM
Quinn Anthony G.Interim CEOJul 12Option Exercise6.7638,866262,76492,793Jul 16 09:04 AM
Quinn Anthony G.Interim CEOJul 11Option Exercise5.463,30718,05653,927Jul 13 09:05 AM
Novartis Bioventures Ltd10% OwnerMay 11Sale10.0619,550196,6732,175,314May 14 04:01 PM
Novartis Bioventures Ltd10% OwnerMay 10Sale10.1322,725230,2042,194,864May 11 04:28 PM
Novartis Bioventures Ltd10% OwnerMay 09Sale10.1151,230517,9352,217,589May 11 04:28 PM
Novartis Bioventures Ltd10% OwnerMay 08Sale10.0326,557266,3672,268,819May 09 04:01 PM
Novartis Bioventures Ltd10% OwnerMay 07Sale10.1115,548157,1902,295,376May 09 04:01 PM
Quinn Anthony G.Interim CEOFeb 15Option Exercise5.4615,21183,05250,620Feb 20 04:36 PM
Quinn Anthony G.Interim CEODec 08Buy5.076003,03935,409Dec 08 07:06 PM
Quinn Anthony G.Interim CEODec 07Buy4.992,80013,96734,809Dec 08 07:06 PM
Quinn Anthony G.Interim CEODec 06Buy4.924,88824,07232,009Dec 08 07:06 PM
York Charles N IIChief Financial Officer and VPDec 05Buy4.7610,24148,70034,787Dec 05 09:07 PM
Quinn Anthony G.DirectorDec 05Buy4.935,06524,97627,121Dec 05 09:04 PM
York Charles N IIChief Financial Officer and VPDec 04Buy4.973,25916,19724,546Dec 05 09:07 PM
Quinn Anthony G.DirectorDec 04Buy4.987,95639,62422,056Dec 05 09:04 PM
York Charles N IIChief Financial Officer and VPDec 01Buy4.596,50029,85521,287Dec 05 09:07 PM
Quinn Anthony G.DirectorDec 01Buy4.534,10018,57814,100Dec 05 09:04 PM
open in yahoo | open in reuters | open in google